v3.26.1
Summary of Significant Accounting Policies - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Research and development $ 20,706 $ 8,704 $ 35,452 $ 19,178
Net loss (26,304) (15,993) (50,527) (33,435)
Reportable Segment        
Segment Reporting [Line Items]        
Stock-based compensation 4,457 3,732 9,465 7,376
Other segment items (3,000) (2,056) (4,261) (3,859)
Net loss 26,304 15,993 50,527 33,435
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Reportable Segment        
Segment Reporting [Line Items]        
Wages and benefits 1,992 2,792 4,678 5,383
Other general and administrative expenses 3,163 3,198 6,775 6,251
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment        
Segment Reporting [Line Items]        
Wages and benefits 3,221 1,794 5,825 3,261
Unallocated research and development expenses 469 476 1,042 931
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab SSc program        
Segment Reporting [Line Items]        
Research and development 4,209 1,430 7,409 4,196
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab HS program        
Segment Reporting [Line Items]        
Research and development 4,688 2,000 9,389 3,274
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab program general        
Segment Reporting [Line Items]        
Research and development 6,929 2,167 9,858 5,871
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Additional product candidates (torudokimab and crebankitug)        
Segment Reporting [Line Items]        
Research and development $ 176 $ 460 $ 347 $ 751